AstraZeneca Gets FDA Approval for Bladder Cancer Treatment
By Katherine Hamilton
AstraZeneca received Food and Drug Administration approval for its drug Imfinzi in combination with other therapies as a treatment for patients with muscle-invasive bladder cancer.
The approval is for Imfinzi used in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after bladder-removal cancer.
The approval is based on results from the Volga Phase 3 trial. Treated patients in the trial demonstrated a 49% reduction in the risk of disease progression or recurrence.
Results from the key secondary endpoint of overall survival showed that the Imfinzi combination reduced the risk of death by 42% compared to the comparison arm.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
November 13, 2026 19:08 ET (00:08 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

